Aptinyx Inc. (NASDAQ:APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. The Phase 2b clinical study was designed to evaluate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback